Pedram Razavi

Pedram Razavi serves as a Clinical Assistant Professor within the Department of Medicine at Memorial Sloan Kettering Cancer Center (MSKCC), where he holds appointments in the Breast Medicine Service and Solid Tumor Oncology Division. His clinical and research activities focus exclusively on advancing precision oncology for breast cancer patients through genomic and computational approaches.

Dr. Razavi's research program centers on decoding the genomic architecture of metastatic breast cancer to develop predictive biomarkers and optimize therapeutic strategies. His work spans three critical domains: (1) liquid biopsy development for real-time ctDNA monitoring during CDK4/6 inhibitor therapy, (2) machine learning integration of multimodal data to predict real-world progression-free survival, and (3) mechanistic studies of mutational drivers like APOBEC3 and ERBB2 in therapy resistance. Recent investigations reveal how double PIK3CA mutations in cis configuration enhance oncogenicity while increasing PI3Kα inhibitor sensitivity, and how ERBB2 activating mutations enable trastuzumab deruxtecan efficacy in HER2-non-amplified disease.

Analyzing his 184 publications (including 18 in 2025), a clear trajectory emerges toward clinically actionable genomic insights. Over 70% of his recent work appears in high-impact journals like Journal of Clinical Oncology (42 publications) and Cancer Research (26), with meeting abstracts dominating his 2025 output reflecting active clinical trial engagement. His research consistently bridges basic mechanisms (e.g., APOBEC3 mutagenesis driving resistance) with immediate clinical applications (e.g., ctDNA dynamics predicting treatment response).

Dr. Razavi maintains an extensive collaborative network centered at MSKCC, with Sarat Chandarlapaty (79 co-publications), Jorge Reis-Filho (67), and Michael Berger (45) representing his core team. He actively participates in international initiatives like the Buenos Aires Breast Cancer Symposium, demonstrating global leadership in translating genomic discoveries into clinical practice for metastatic breast cancer.